OBJECTIVES To summarize the contribution of Latin America (LA) to ISPOR conferences. METHODS We searched the ISPOR study digest from inception in 1998 to 2008 using all LA country names. For each ISPOR meeting (International, European, Asian, and Latin American), we obtained a list of all abstracts classified as being from LA. We also obtained the total numbers of abstracts for each meeting from the database. After eliminating duplicates, we plotted numbers of abstracts and percentages from LA over time. We performed a content analysis, classifying abstracts by aspect (tool development, methodology, policy/guidelines, application), domain (economic, clinical, humanistic, other), and subtype of study. Drugs were categorized according to the Anatomical Therapeutic Classification system. Descriptive statistics were applied by year, country, and study type. RESULTS A total of 281 abstracts were identified; 27 were rejected (not from Latin America) and 11 presented data from more than one country, leaving 227 abstract presentations. However, 7 were presented twice (at different meetings), leaving 220 unique abstracts. They represented 17 different countries; most represented were Brazil (102, 40.2%), Mexico (78, 30.7%), Argentina (21, 8.3%), and Colombia (16, 6.3%). There have been none from Costa Rica, Dominican Republic, French Guiana, Guatemala, or Haiti; others had <10 each. There were 122 (48%) at International meetings, 90 (35%) at European meetings, 42 (17%) at Latin American and none at Asian conferences. Latin American abstracts comprised 2.4% of the 10,401 total. Over time, cumulative numbers of abstracts are increasing exponentially. The majority of abstracts were economic studies (160, 72.7%), followed by humanistic (34, 15.5%), clinical (20, 9.1%), and others (6, 2.7%). Most common drugs examined were antineoplastic/immunomodulators (n=85, 32.3%), systemic anti-infectives (n=65, 24.7%), CNS drugs (N=53, 20.2%), cardiovascular (n=22, 8.4%), and musculo-skeletal (n=16, 6.1%), comprising 91.6% of all drugs. CONCLUSIONS Latin America's contribution is modest, but rapidly increasing.